GlobeImmune, a developer of therapeutic drugs for cancer and infectious diseases, filed on Tuesday with the SEC to raise up to $69 million in an initial public offering. The company has four product candidates in five ongoing clinical trials.
The Louisville, CO-based company has two strategic collaborations, one with Celgene for all oncology related product candidates and the other with Gilead Sciences for chronic hepatitis B virus.
GlobeImmune, which was founded in 1995 and booked $7 million in sales for the 12 months ended 3/31/2012, plans to list on the NASDAQ under the symbol GBIM. Wells Fargo Securities and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
